189 related articles for article (PubMed ID: 37688579)
1. Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survival.
Kim J; Vaksman Z; Egolf LE; Kaufman R; Evans JP; Conkrite KL; Danesh A; Lopez G; Randall MP; Dent MH; Farra LM; Menghani NL; Dymek M; Desai H; Hausler R; Hicks B; Auvil JG; Gerhard DS; Hakonarson H; Maxwell KN; Cole KA; Pugh TJ; Bosse KR; Khan J; Wei JS; Maris JM; Stewart DR; Diskin SJ
J Natl Cancer Inst; 2024 Jan; 116(1):149-159. PubMed ID: 37688579
[TBL] [Abstract][Full Text] [Related]
2. Germline pathogenic variants in 786 neuroblastoma patients.
Kim J; Vaksman Z; Egolf LE; Kaufman R; Evans JP; Conkrite KL; Danesh A; Lopez G; Randall MP; Dent MH; Farra LM; Menghani N; Dymek M; Desai H; Hausler R; ; ; ; Auvil JG; Gerhard DS; Hakonarson H; Maxwell KN; Cole KA; Pugh TJ; Bosse KR; Khan J; Wei JS; Maris JM; Stewart DR; Diskin SJ
medRxiv; 2023 Jan; ():. PubMed ID: 36747619
[TBL] [Abstract][Full Text] [Related]
3. BARD1 germline variants induce haploinsufficiency and DNA repair defects in neuroblastoma.
Randall MP; Egolf LE; Vaksman Z; Samanta M; Tsang M; Groff D; Evans JP; Rokita JL; Layeghifard M; Shlien A; Maris JM; Diskin SJ; Bosse KR
J Natl Cancer Inst; 2024 Jan; 116(1):138-148. PubMed ID: 37688570
[TBL] [Abstract][Full Text] [Related]
4. Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer.
Weber-Lassalle N; Borde J; Weber-Lassalle K; Horváth J; Niederacher D; Arnold N; Kaulfuß S; Ernst C; Paul VG; Honisch E; Klaschik K; Volk AE; Kubisch C; Rapp S; Lichey N; Altmüller J; Lepkes L; Pohl-Rescigno E; Thiele H; Nürnberg P; Larsen M; Richters L; Rhiem K; Wappenschmidt B; Engel C; Meindl A; Schmutzler RK; Hahnen E; Hauke J
Breast Cancer Res; 2019 Apr; 21(1):55. PubMed ID: 31036035
[TBL] [Abstract][Full Text] [Related]
5.
Randall MP; Egolf LE; Vaksman Z; Samanta M; Tsang M; Groff D; Evans JP; Rokita JL; Layeghifard M; Shlien A; Maris JM; Diskin SJ; Bosse KR
bioRxiv; 2023 Feb; ():. PubMed ID: 36778420
[TBL] [Abstract][Full Text] [Related]
6. Apparent regional differences in the spectrum of BARD1 pathogenic variants in Spanish population and importance of copy number variants.
Benito-Sánchez B; Barroso A; Fernández V; Mercadillo F; Núñez-Torres R; Pita G; Pombo L; Morales-Chamorro R; Cano-Cano JM; Urioste M; González-Neira A; Osorio A
Sci Rep; 2022 May; 12(1):8547. PubMed ID: 35595798
[TBL] [Abstract][Full Text] [Related]
7. Variant Identification in BARD1, PRDM9, RCC1, and RECQL in Patients with Ovarian Cancer by Targeted Next-generation Sequencing of DNA Pools.
Suszynska M; Ratajska M; Galka-Marciniak P; Ryszkowska A; Wydra D; Debniak J; Jasiak A; Wasag B; Cybulski C; Kozlowski P
Cancer Prev Res (Phila); 2022 Mar; 15(3):151-160. PubMed ID: 34906988
[TBL] [Abstract][Full Text] [Related]
8.
Rofes P; Del Valle J; Torres-Esquius S; Feliubadaló L; Stradella A; Moreno-Cabrera JM; López-Doriga A; Munté E; De Cid R; Campos O; Cuesta R; Teulé Á; Grau È; Sanz J; Capellá G; Díez O; Brunet J; Balmaña J; Lázaro C
Genes (Basel); 2021 Jan; 12(2):. PubMed ID: 33498765
[TBL] [Abstract][Full Text] [Related]
9. Frequent incidence of BARD1-truncating mutations in germline DNA from triple-negative breast cancer patients.
De Brakeleer S; De Grève J; Desmedt C; Joris S; Sotiriou C; Piccart M; Pauwels I; Teugels E
Clin Genet; 2016 Mar; 89(3):336-40. PubMed ID: 26010302
[TBL] [Abstract][Full Text] [Related]
10. Functional analysis of clinical
Toh MR; Chong ST; Chan SH; Low CE; Ishak NDB; Lim JQ; Courtney E; Ngeow J
Cold Spring Harb Mol Case Stud; 2019 Aug; 5(4):. PubMed ID: 31371347
[TBL] [Abstract][Full Text] [Related]
11. Associations Between Cancer Predisposition Testing Panel Genes and Breast Cancer.
Couch FJ; Shimelis H; Hu C; Hart SN; Polley EC; Na J; Hallberg E; Moore R; Thomas A; Lilyquist J; Feng B; McFarland R; Pesaran T; Huether R; LaDuca H; Chao EC; Goldgar DE; Dolinsky JS
JAMA Oncol; 2017 Sep; 3(9):1190-1196. PubMed ID: 28418444
[TBL] [Abstract][Full Text] [Related]
12. Fine mapping of 2q35 high-risk neuroblastoma locus reveals independent functional risk variants and suggests full-length BARD1 as tumor-suppressor.
Cimmino F; Avitabile M; Diskin SJ; Vaksman Z; Pignataro P; Formicola D; Cardinale A; Testori A; Koster J; de Torres C; Devoto M; Maris JM; Iolascon A; Capasso M
Int J Cancer; 2018 Dec; 143(11):2828-2837. PubMed ID: 30132831
[TBL] [Abstract][Full Text] [Related]
13. Literature Review of
Alenezi WM; Fierheller CT; Recio N; Tonin PN
Genes (Basel); 2020 Jul; 11(8):. PubMed ID: 32726901
[TBL] [Abstract][Full Text] [Related]
14. Variants of cancer susceptibility genes in Korean BRCA1/2 mutation-negative patients with high risk for hereditary breast cancer.
Park JS; Lee ST; Nam EJ; Han JW; Lee JY; Kim J; Kim TI; Park HS
BMC Cancer; 2018 Jan; 18(1):83. PubMed ID: 29338689
[TBL] [Abstract][Full Text] [Related]
15. Prevalence and Prognostic Role of BRCA1/2 Variants in Unselected Chinese Breast Cancer Patients.
Zhong X; Dong Z; Dong H; Li J; Peng Z; Deng L; Zhu X; Sun Y; Lu X; Shen F; Su X; Zhang L; Gu Y; Zheng H
PLoS One; 2016; 11(6):e0156789. PubMed ID: 27257965
[TBL] [Abstract][Full Text] [Related]
16. Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.
Ramus SJ; Song H; Dicks E; Tyrer JP; Rosenthal AN; Intermaggio MP; Fraser L; Gentry-Maharaj A; Hayward J; Philpott S; Anderson C; Edlund CK; Conti D; Harrington P; Barrowdale D; Bowtell DD; Alsop K; Mitchell G; ; Cicek MS; Cunningham JM; Fridley BL; Alsop J; Jimenez-Linan M; Poblete S; Lele S; Sucheston-Campbell L; Moysich KB; Sieh W; McGuire V; Lester J; Bogdanova N; Dürst M; Hillemanns P; ; Odunsi K; Whittemore AS; Karlan BY; Dörk T; Goode EL; Menon U; Jacobs IJ; Antoniou AC; Pharoah PD; Gayther SA
J Natl Cancer Inst; 2015 Nov; 107(11):. PubMed ID: 26315354
[TBL] [Abstract][Full Text] [Related]
17. Tumor sequencing is useful to refine the analysis of germline variants in unexplained high-risk breast cancer families.
Van Marcke C; Helaers R; De Leener A; Merhi A; Schoonjans CA; Ambroise J; Galant C; Delrée P; Rothé F; Bar I; Khoury E; Brouillard P; Canon JL; Vuylsteke P; Machiels JP; Berlière M; Limaye N; Vikkula M; Duhoux FP
Breast Cancer Res; 2020 Apr; 22(1):36. PubMed ID: 32295625
[TBL] [Abstract][Full Text] [Related]
18. Frequency of germline DNA genetic findings in an unselected prospective cohort of triple-negative breast cancer patients participating in a platinum-based neoadjuvant chemotherapy trial.
González-Rivera M; Lobo M; López-Tarruella S; Jerez Y; Del Monte-Millán M; Massarrah T; Ramos-Medina R; Ocaña I; Picornell A; Santillán Garzón S; Pérez-Carbornero L; García-Saenz JA; Gómez H; Moreno F; Márquez-Rodas I; Fuentes H; Martin M
Breast Cancer Res Treat; 2016 Apr; 156(3):507-515. PubMed ID: 27083178
[TBL] [Abstract][Full Text] [Related]
19. Replication of GWAS-identified neuroblastoma risk loci strengthens the role of BARD1 and affirms the cumulative effect of genetic variations on disease susceptibility.
Capasso M; Diskin SJ; Totaro F; Longo L; De Mariano M; Russo R; Cimmino F; Hakonarson H; Tonini GP; Devoto M; Maris JM; Iolascon A
Carcinogenesis; 2013 Mar; 34(3):605-11. PubMed ID: 23222812
[TBL] [Abstract][Full Text] [Related]
20. The Association between GWAS-identified BARD1 Gene SNPs and Neuroblastoma Susceptibility in a Southern Chinese Population.
Zhang R; Zou Y; Zhu J; Zeng X; Yang T; Wang F; He J; Xia H
Int J Med Sci; 2016; 13(2):133-8. PubMed ID: 26941572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
